Nathalie Albert
LightNews LightNews
banner
nathaliealbert.bsky.social
Nathalie Albert
@nathaliealbert.bsky.social
53 followers 25 following 0 posts
Professor of Nuclear Medicine with a focus on Neurooncology, passionate for PET imaging and theranostics, founder of the Female Excellence in Medicine Network (FEMclub)
Posts Replies Media Videos
Reposted by Nathalie Albert
lmumuenchen.bsky.social
An international research team led by nuclear medicine specialist @nathaliealbert.bsky.social (@lmu-klinikum.bsky.social) and oncologist Matthias Preusser (@meduniwien.ac.at) have taken an important step towards improving the diagnosis and therapy monitoring of brain metastases. Read more here:
Nuclear medicine: better diagnosis and therapy for brain metastases
An international team of researchers lays down the first ever standardized criteria for the use of amino acid PET for brain metastases.
www.lmu.de
May 12, 2025 at 6:48 AM
Reposted by Nathalie Albert
nmnsymposium.bsky.social
🥳 Today, the first patient was successfully randomized in the international LUMEN-1 trial, the first prospective randomized study to evaluate the efficacy of [177Lu]Lu-DOTATATE in recurrent meningioma!
www.eortc.org/research_fie...
@nathaliealbert.bsky.social @eortc.org
May 15, 2025 at 3:32 PM
Reposted by Nathalie Albert
nmnsymposium.bsky.social
📡 Listen to the @neuroonc.bsky.social podcast with @nathaliealbert.bsky.social on measurable disease with FET-PET vs. MRI in glioblastoma: soc-neuro-onc.libsyn.com/measurable-d...!
@eanoassociation.bsky.social @eortc.bsky.social
February 9, 2025 at 9:41 AM
Reposted by Nathalie Albert
nmnsymposium.bsky.social
💥 @nathaliealbert.bsky.social highlighting the randomized LUMEN-1 trial on Lu-DOTATE in recurrent #meningioma in @naturemedicine.bsky.social: nature.com/articles/d41....

@eortc.bsky.social @eanoassociation.bsky.social @neuroonc.bsky.social @icomeningioma.bsky.social #theranostics
February 11, 2025 at 11:19 AM
Reposted by Nathalie Albert
jmwerner.bsky.social
🚨 Study by Galldiks et al. showing metabolic response to vorasidenib in IDH-mut gliomas using PET monitoring. This highlights FET PET’s potential to provide earlier & more informative assessments of treatment response than MRI in patients receiving IDH-inhibitors
academic.oup.com/noa/advance-...
Evaluation of early metabolic changes following vorasidenib using FET PET in patients with IDH-mutant gliomas
SUMMARY. The phase-3 INDIGO trial demonstrated that the IDH inhibitor vorasidenib significantly prolonged progression-free survival and delayed interventio
academic.oup.com
November 29, 2024 at 4:21 PM
Reposted by Nathalie Albert
femclub.bsky.social
Welcome to FEMclub – where women in medicine come together to inspire, innovate, and make waves! 💥

Join us and become part of the community!
https://buff.ly/3Vhkwi4

#FEMclub #rolemodel #rolemodels #vorbild #femalescientist #equality #medicine #med
December 7, 2024 at 7:27 AM
Reposted by Nathalie Albert
femclub.bsky.social
Welcome to the FEMclub @bsky.app!
At FEMclub, we believe in surrounding ourselves with brilliance, inspiration, and diverse perspectives. 🧠💡
We love to inspire and to get inspired by our amazing FEMclub members. 

We're certainly all in the right room here. 
Join us! 
www.femclubmed.org
December 3, 2024 at 4:24 AM
Reposted by Nathalie Albert
eanoassociation.bsky.social
That’s a wrap on #SNO2024 in Houston! ✨ The #EANO team had an amazing time sharing knowledge, meeting outstanding colleagues and friends, and being part of such an inspiring event. Thank you, @neuroonc.bsky.social, for hosting this great conference!

#neurooncology #braintumor #cancer #btsm
November 24, 2024 at 4:19 PM